The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2022

Filed:

Jan. 11, 2016
Applicant:

Pieris Pharmaceuticals Gmbh, Freising-Weihenstephan, DE;

Inventor:

Marlon Hinner, Munich, DE;

Assignee:

Pieris Pharmaceuticals GmbH, Freising-Weihensteph, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C07K 14/725 (2006.01); C07K 14/47 (2006.01); C07K 14/54 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); C07K 14/47 (2013.01); C07K 14/5434 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70596 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C07K 2318/20 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/22 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01);
Abstract

Lipocalin muteins specific to a predetermined antigen can be transduced into a T cell to bring therapeutic benefits to patients in need. In one example, a lipocalin mutein specific to a predetermined antigen (e.g., a target differentially expressed on the surface of a tumor cell) can be transduced into a T cell membrane to serve as an antigen receptor, offering benefits over conventionally deployed antibody-derived protein moieties such as a single chain variable fragment (scFv). Benefits include a more stable structure, leading to superior target engagement, for example. Further, lipocalin muteins specific to a predetermined antigen (e.g. an immunomodulatory target such as an immune checkpoint or costimulatory molecule) can be transduced into a T cell for secretion thereby, bringing an added therapeutic benefit. Specific examples of such modified T cells and methods of making and using the same are provided herein.


Find Patent Forward Citations

Loading…